| scholarly article | Q13442814 |
| P2093 | author name string | Cleary PE | |
| Goggin M | |||
| Minihan M | |||
| P2860 | cites work | Visual Field Loss After Pars Plana Vitrectomy With Air/Fluid Exchange | Q72026638 |
| Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2 | Q72071892 | ||
| Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study | Q72261225 | ||
| Pars plana vitrectomy for treatment of stage 2 macular holes | Q72296408 | ||
| Posterior segment complications after vitrectomy for macular hole | Q72303353 | ||
| Reappraisal of biomicroscopic classification of stages of development of a macular hole | Q72324397 | ||
| Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes | Q72419475 | ||
| Adjunctive mitomycin C in Molteno implant surgery | Q72432545 | ||
| Infective endophthalmitis following vitreoretinal surgery | Q72638279 | ||
| Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study | Q72652792 | ||
| Results of surgical treatment of recent-onset full-thickness idiopathic macular holes | Q72889814 | ||
| Human autologous serum for the treatment of full-thickness macular holes. A preliminary study | Q73274976 | ||
| Laser treatment of macular holes. | Q36436713 | ||
| Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study | Q36797701 | ||
| Visual field loss following vitrectomy for stage 2 and 3 macular holes | Q37321300 | ||
| Vitreous surgery for macular holes | Q39490024 | ||
| Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo | Q43602174 | ||
| Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study | Q43734011 | ||
| Visual field loss after macular hole surgery. | Q51026048 | ||
| Bilateral visual function after macular hole surgery. | Q64928961 | ||
| Idiopathic senile macular hole. Its early stages and pathogenesis | Q68320462 | ||
| Apparent disappearance of a macular hole associated with development of an epiretinal membrane | Q69583585 | ||
| Transforming growth factor beta. A biologic chorioretinal glue | Q69584973 | ||
| Vitreous surgery for macular hole in perspective. Is there an indication? | Q70145923 | ||
| Vitreous surgery for idiopathic macular holes. Results of a pilot study | Q70145928 | ||
| The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes | Q70760006 | ||
| Autologous platelet concentrate for the treatment of full-thickness macular holes | Q70841819 | ||
| Treatment of retinal breaks with autologous serum in an experimental model | Q71674815 | ||
| Reoperation after failed macular hole surgery | Q71798093 | ||
| Macular holes | Q71936075 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1073-1079 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. | |
| P478 | volume | 81 |
| Q36073834 | Anatomical success rate of macular hole surgery with autologous platelet without internal-limiting membrane peeling |
| Q36785085 | Efficacy of autologous platelets in macular hole surgery |
| Q45959577 | Equivalent tamponade by room air as compared with SF(6) after macular hole surgery. |
| Q50228566 | Idiopathic macular hole: analysis of visual outcomes and the use of indocyanine green or brilliant blue for internal limiting membrane peel. |
| Q33991648 | Internal limiting membrane removal in the management of full-thickness macular holes |
| Q33882407 | Intraoperative adjunctive agents in vitrectomy: serum, cytokines, and glue |
| Q40126725 | Macular slippage after macular hole surgery with internal limiting membrane peeling |
| Q36275852 | Management of Stage IV Macular Holes: When Standard Surgery Fails |
| Q28362444 | Phacovitrectomy without prone posture for full thickness macular holes |
| Q35314255 | Prevention of visual field defects after macular hole surgery |
| Q44259863 | Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment |
| Q37064683 | Spontaneous closure of macular hole following blunt trauma. |
| Q39389599 | Spontaneous traumatic macular hole closure in a 50-year-old woman: a case report. |
| Q73065973 | Surgery for full-thickness macular holes with short-duration prone posturing: results of a pilot study |
| Q43653247 | Surgical management of macular holes: a report by the American Academy of Ophthalmology |
| Q33954844 | Update on current surgical management of idiopathic macular holes |
Search more.